Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
June 27, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
June 12, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
June 05, 2023 08:00 ET
|
Windtree Therapeutics
Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a...
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
May 15, 2023 16:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
April 27, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage...
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
April 24, 2023 16:01 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
April 20, 2023 08:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
April 17, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
April 03, 2023 07:35 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...
Windtree Regains Compliance with Nasdaq
March 13, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...